<DOC>
	<DOCNO>NCT01204762</DOCNO>
	<brief_summary>At least 1 dose pegIFNÎ» identify safe , well tolerate , efficacious treatment chronic hepatitis B virus infection ( CHB ) Amendment 7 , Part B Sub Study : The primary purpose amendment obtain preliminary data safety pegylated interferon Lambda ( Lambda ) administer combination Entecavir ( ETV ) patient hepatitis E antigen-positive ( HBeAg-positive ) chronic hepatitis B ( CHB ) infection employ sequential therapy approach</brief_summary>
	<brief_title>Dose Ranging Study Pegylated Interferon Lambda Patients With Hepatitis B Positive Hepatitis B e Antigen</brief_title>
	<detailed_description>Part B sub study Open Label</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Interferons</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Infection hepatitis B virus ( HBV ) positive hepatitis B e antigen Between age 18 70 Have previously treat interferon HBV nucleos ( ) idenaive Not infect hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) human immunodeficiency virus ( HIV ) Do serious liver , psychiatric , blood , thyroid , lung , heart eye disease Able tolerate oral medication</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>